Nordic Nanovector and APIM Therapeutics Announce Merger Agreement
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. · Merger to create a clinical-stage biotechnology company focused on advancing a portfolio of oncology programmes including a Phase 1b/2a clinical study in platinum-sensitive ovarian cancer and a Phase 2 clinical study in sarcoma · Combined company is expected to have funding into 2024 · Companies will host a joint webcast on 10 November 2022 at 10:00 a.m. CET. The